Tears Naturale Forte
PreclinicalSmall molecule
Tears Naturale Forte is one of 27 small molecule programs targeting Dry Eye Syndrome. It is currently in Preclinical.
2
Indications
5
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Dry Eye Syndrome
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Estrace
Novo NordiskApproved
Aldactone
PfizerApproved
Revia
TevaApproved
Xeljanz
PPrism Pharmaceuticals
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Isopto Carpine
AAdvanz Pharma
Approved
Chantix
PPrism Pharmaceuticals
Approved
Tobrex
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Dry Eye Syndrome2 trials
Meibomian Gland Dysfunction2 trials
Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?
Unknown status·—·N/A·NCT03060005·80 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tears Naturale Forte. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSun Yat-sen University